RecruitingPhase 2NCT06595186

JK-1201I Combined with Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

Studying Giant cell glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
JenKem Technology Co., Ltd.
Intervention
JK-1201I(drug)
Enrollment
25 enrolled
Eligibility
18-75 years · All sexes
Timeline
20222026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06595186 on ClinicalTrials.gov

Other trials for Giant cell glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Giant cell glioblastoma

← Back to all trials